3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
6
Recruiting
4
Active not recruiting
4
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
35
Cisplatin
24
fludarabine
23
Radiotherapy
23
Paclitaxel
21
Carboplatin
20
pembrolizumab
18
Nivolumab
18
Magnetic Resonance Spectroscopy
18
Specimen Handling
17
fludarabine phosphate
15
Gemcitabine
15
Biopsy
15
Cytarabine
14
Radiation
11
Filgrastim
11
Doxorubicin
11
Docetaxel
11
Dexamethasone
11
Radiosurgery
10
Granulocyte Colony-Stimulating Factor
10
Etoposide
10
Melphalan
9
Ipilimumab
9
venetoclax
8
Rituximab
8
Calcium Dobesilate
8
trametinib
7
ibrutinib
7
durvalumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Withdrawn
×
zimberelimab
×
Clear all
NCT04892875
2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1
Withdrawn